Rifaquizinone
Hyperammonemia
TenNor Therapeutics (Suzhou) LimitedSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Hyperammonemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hepastem Cellaion SA | Phase 1/2 | CCC |
Glycerol Phenylbutyrate Amgen | Phase 1 | CC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →